Specific detection of type II human chorionic gonadotropin beta subunit produced by trophoblastic and neoplastic cells

Aldaz-Carroll, Lydia; Richon, Sophie; Dangles‐Marie, Virginie; Fournier, Thierry; Troalen, Frédéric; Stevens, D.U.; Guery, Benoît; Hersant, A.-M.; Gadrey, Jean; Nordor, Akpeli V.; Pecking, A; Bellet, Dominique

doi:10.1016/j.cca.2015.02.009

Cited by 7 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ß CG promoters may differ between trisomy 21-affected pregnancies and normal pregnancies. The sequence and amino acid composition of intact hCG remain unchanged [66], while levels of urinary β core are increased in trisomy 21-affected pregnancies, reflecting an increase in both hCG levels and catabolism [67].…”

Section: Figurementioning

confidence: 97%

Biochemical Screening for Fetal Trisomy 21: Pathophysiology of Maternal Serum Markers and Involvement of the Placenta

Gadrey

Leguy

Pidoux

et al. 2023

IJMS

View full text Add to dashboard Cite

It is now well established that maternal serum markers are often abnormal in fetal trisomy 21. Their determination is recommended for prenatal screening and pregnancy follow-up. However, mechanisms leading to abnormal maternal serum levels of such markers are still debated. Our objective was to help clinicians and scientists unravel the pathophysiology of these markers via a review of the main studies published in this field, both in vivo and in vitro, focusing on the six most widely used markers (hCG, its free subunit hCGβ, PAPP-A, AFP, uE3, and inhibin A) as well as cell-free feto–placental DNA. Analysis of the literature shows that mechanisms underlying each marker’s regulation are multiple and not necessarily directly linked with the supernumerary chromosome 21. The crucial involvement of the placenta is also highlighted, which could be defective in one or several of its functions (turnover and apoptosis, endocrine production, and feto–maternal exchanges and transfer). These defects were neither constant nor specific for trisomy 21, and might be more or less pronounced, reflecting a high variability in placental immaturity and alteration. This explains why maternal serum markers can lack both specificity and sensitivity, and are thus restricted to screening.

show abstract

Section: Figurementioning

confidence: 97%

Biochemical Screening for Fetal Trisomy 21: Pathophysiology of Maternal Serum Markers and Involvement of the Placenta

Gadrey

Leguy

Pidoux

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…CGB1 and CGB2 might encode a protein unrelated to hCG, while the rest four genes encode the two specific hCGβ proteins. CGB7 encodes a protein with an alanine at position 117, while CGB3, CGB5, and CGB8 encode an aspartic acid at this position [8]. According to this difference, CGB7 was classified into type I gene, while the other three (CGB3, CGB5, and CGB8) were classified into type II genes [9].…”

Section: Original Researchmentioning

confidence: 99%

CGB5 expression is independently associated with poor overall survival and recurrence‐free survival in patients with advanced gastric cancer

et al. 2018

View full text Add to dashboard Cite

The human CGB5 gene encodes chorionic gonadotropin (hCG)β 5, which is aberrantly expressed in trophoblastic neoplasm and in some non‐trophoblastic neoplasms. Fucntional studies observed that it involved tumor initiation, growth, and metastatic outgrowth. In this study, using data from the International Cancer Genome Consortium (ICGC) and the Cancer Genome Atlas (TCGA)‐stomach adenocarcinoma (STAD), we assessed the independent prognostic value of CGB5 expression in patients with primary gastric cancer (GC). Results showed that CGB5 expression was nearly not expressed in normal GC tissues. In comparison, its expression was detected in 214 of the 415 primary GC cases (51.6%) in TCGA‐STAD and was associated with poor response to primary therapy and a higher risk of recurrence and death. In early stages, CGB5 expression was not a prognostic factor in terms of OS (HR: 1.448; 95% CI: 0.811–2.588, P = 0.211) or RFS (HR: 1.659; 95% CI: 0.778–3.540, P = 0.190). However, its expression was independently associated with unfavorable OS (HR: 1.719; 95% CI: 1.115–2.651, P = 0.014) and RFS (HR: 3.602; 95% CI: 1.708–7.598, P = 0.001) in advanced stages. Using deep sequencing data from TCGA‐STAD , we found that CGB5 expression was not related to its genetic amplification or DNA methylation in GC. Based on these findings, we infer that CGB5 expression is common in GC patients and its expression might independently predict poor OS and RFS in advanced stages, but not in early stages of GC.

show abstract

Neel Effect: Exploiting the Nonlinear Behavior of Superparamagnetic Nanoparticles for Applications in Life Sciences up to Electrical Engineering

Lenglet

Motte

2018

Novel Magnetic Nanostructures

View full text Add to dashboard Cite

Specific detection of type II human chorionic gonadotropin beta subunit produced by trophoblastic and neoplastic cells

Abstract: Type II gene expression can be detected using FBT11-II. This specific recognition could improve the clinical usefulness of assays aimed at either managing aggressive tumors or screening for Down syndrome.

Cited by 7 publications

References 40 publications

Biochemical Screening for Fetal Trisomy 21: Pathophysiology of Maternal Serum Markers and Involvement of the Placenta

Biochemical Screening for Fetal Trisomy 21: Pathophysiology of Maternal Serum Markers and Involvement of the Placenta

CGB5 expression is independently associated with poor overall survival and recurrence‐free survival in patients with advanced gastric cancer

Neel Effect: Exploiting the Nonlinear Behavior of Superparamagnetic Nanoparticles for Applications in Life Sciences up to Electrical Engineering

Contact Info

Product

Resources

About